GABA Agonists clinical trials
A class of medicines: the studies that test any of its 3 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Adipiplon
- 1
Studies by the year they started
23 studies that test it; most in 2004 (6)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 3
H. Lundbeck A/S (10) · Ovid Therapeutics Inc. (3) · Bellus Health Inc. - a GSK company (3) · Healx AI (2) · Craig Erickson (1) · Vanderbilt University Medical Center (1) · Neurogen Corporation (1) · Aristotle University Of Thessaloniki (1)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 23
- Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)CompletedPhase 2Craig EricksonNCT06334419Written as GaboxadolHow we know
- A Study in Adults and Adolescents With Angelman Syndrome (STARS)CompletedPhase 2Healx AINCT02996305Written as OV101 Regimen 1How we know
- An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeTerminatedPhase 3Healx AINCT03882918Written as OV101How we know
- A Study of OV101 in Individuals With Fragile X SyndromeCompletedPhase 2Ovid Therapeutics Inc.NCT03697161Written as OV101 (gaboxadol)How we know
- A Study of OV101 in Individuals With Angelman Syndrome (AS)CompletedPhase 3Ovid Therapeutics Inc.NCT04106557Written as GaboxadolHow we know
- Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40WithdrawnPhase 2Healx LimitedNCT04823052Written as Gaboxadol (HLX-0206)How we know
- The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive ImpairmentStatus unknownPhase 4Aristotle University Of ThessalonikiNCT05022186Written as HomotaurineHow we know
- Single Dose Pharmacokinetic (PK) StudyCompletedPhase 1Ovid Therapeutics Inc.NCT03109756Written as OV101How we know
- How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care UnitsTerminatedPhase 1Vanderbilt University Medical CenterNCT00826553Written as GABA agonistHow we know
- Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00095043Written as MK0928, gaboxadolHow we know
- Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00094627Written as gaboxadolHow we know
- Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00102167Written as gaboxadolHow we know
- An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)CompletedPhase 3H. Lundbeck A/SNCT00103818Written as gaboxadolHow we know
- Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderCompletedPhase 2H. Lundbeck A/SNCT00807248Written as Gaboxadol 5 mgHow we know
- Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary InsomniacsTerminatedPhase 2Neurogen CorporationNCT00683436Written as AdipiplonHow we know
- European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsStatus unknownPhase 3Bellus Health Inc. - a GSK companyNCT00217763Written as 3APSHow we know
- Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownPhase 3Bellus Health Inc. - a GSK companyNCT00314912Written as Tramiprosate (3APS)How we know
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209846Written as GaboxadolHow we know
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209963Written as GaboxadolHow we know
- A Study of Gaboxadol in Primary InsomniaCompletedPhase 3H. Lundbeck A/SNCT00209924Written as GaboxadolHow we know
Codes
What other systems call GABA Agonists · ClinicalTrials.gg INT008649
- MeSH (NLM) D018755GABA AgonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D018755 | GABA Agonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.